Evaxion appoints Helen Tayton-Martin as new CEO

Danish clinical-stage techbio, Evaxion (Nasdaq: EVAX), which is specializing in developing AI-Immunology powered vaccines, has appointed Dr Helen Tayton-Martin as new chief executive (CEO). She will take up her new position on November 24, 2025, and simultaneously step down from Evaxion’s board of directors.

Dr Tayton-Martin was a co-founder of cancer-focused biotech company Adaptimmune, where she served as chief operating officer and later chief business & strategy officer during her 17 years with the company. Through this time, she oversaw transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. Dr Tayton-Martin was responsible for all Adaptimmune’s strategic partnerships including those with Astellas (TYO: 4503), Roche (ROG: SIX) subsidiary Genentech, GlaxoSmithKline (LSE: GSK) and Galapagos (Euronext: GLPG).

Prior to Adaptimmune, Dr Tayton Martin spent 15 years working within the pharma, biotech and consulting environments for various companies. She also previously served as a non-executive director of Trillium Therapeutics from October 2017 through to the sale of the company in November 2021 to Pfizer.